<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670149</url>
  </required_header>
  <id_info>
    <org_study_id>12072</org_study_id>
    <secondary_id>2012-003205-10</secondary_id>
    <nct_id>NCT01670149</nct_id>
  </id_info>
  <brief_title>Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea</brief_title>
  <acronym>RAPID</acronym>
  <official_title>A Randomised Placebo Controlled Trial of &quot;Follow on&quot; Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridium difficile associated diarrhoea is an important cause of morbidity in patients
      treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of
      initially successful treatments for colitis. Preliminary reports suggest that Rifaximin, a
      poorly absorbed antibiotic used to treat travellers diarrhoea can prevent relapse. We plan
      to carry out a randomised placebo controlled trial to test the hypothesis that Rifaximin
      given in a reducing dose over 4 weeks after successful treatment will reduce the relapse
      rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims i) To examine efficacy of a follow-on course of Rifaximin given after a successful
      initial course of standard treatment, in the prevention of relapse in C. difficile
      associated diarrhoea (CDAD).

      ii) To examine changes in faecal microbiota in patients given Rifaximin vs. Placebo.

      Treatment 4 weeks treatment with Rifaximin or Placebo tablets. Tapering dose starting with 2
      x 200mg tablets three times a day (total = 1.2g per day) for the 1st 2 weeks, reduced to 1 x
      200mg tablet three times a day (total = 0.6g per day) for the 2nd 2 weeks.

      Primary endpoint:  The difference in % relapse between Rifaximin and placebo at 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Difference in % relapse between Rifaximin and placebo at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference in % relapse between Rifaximin and placebo at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion relapsed, re-hospitalisation and bowel symptoms</measure>
    <time_frame>12 weeks - 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary endpoints:
Clinical:
Proportion with relapse of CDAD within 6 months
Proportion re-hospitalised for CDAD within 6 months
Length of in-hospital stay following start of treatment
Exploratory:
Stool frequency and consistency during 12 weeks after start of treatment
Microbiological assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical looking tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin , Xifaxanta™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Rifaximin , Xifaxanta™</arm_group_label>
    <other_name>Xifaxanta™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Men / Women aged 18 and over (We will also include those adults who lack mental
             capacity for whom we have a legal representative)

          2. Successful treatment of clinically diagnosed CDAD using standard therapy
             (metronidazole or vancomycin given according to standard local hospital guidelines).

        Exclusion criteria:

          1. Woman of child bearing potential and not willing to use at least one highly effective
             contraceptive method throughout the study

          2. Male with spouse/partner of child bearing potential and not willing to use condoms

          3. Pregnant or breast feeding

          4. Unable to swallow tablets

          5. Unable to stop chronic antibiotic use

          6. Life expectancy of &lt;4 weeks

          7. Hypersensitivity to the active substance, to any rifamycin (e.g. rifampicin or
             rifabutin) or to any of its excipients (Tablet core: Sodium starch glycolate type A,
             glycerol distearate, colloidal anhydrous, silica, talc and microcrystalline
             cellulose. Tablet coating: hypromellose, titanium dioxide (E171), disodium edentate,
             propylene glycol and red iron oxide E172)

          8. &gt;5 days post standard therapy (metronidazole or vancomycin) for clinically diagnosed
             CDAD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida Jawhari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aida Jawhari, MD</last_name>
    <phone>+441159249924</phone>
    <phone_ext>66086</phone_ext>
    <email>aida.jawhari@nuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin C Spiller, MD</last_name>
    <phone>1158231090</phone>
    <email>robin.spiller@nottingham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nottingham Clinical Trials Unit (NCTU), Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nafisa Boota, BSc (Hons)</last_name>
      <phone>+44 (0)115 884 4924</phone>
      <email>Nafisa.Boota@nottingham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Robin c Spiller, MD</last_name>
      <phone>+44 (0)115 8231090</phone>
      <email>robin.spiller@nottingham.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Aida Jawhari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giles Major, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Diarrhoea</keyword>
  <keyword>Rifaximin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
